Medical Pharmacology: Chapter: General Anesthesia — Chapter 14 -- Module: GA-03 — CNS and Cardiovascular Effects of Inhalational Anesthetics

Chapter: General Anesthesia — Chapter 14 — Module: GA-03 — CNS and Cardiovascular Effects of Inhalational Anesthetics
Tier: Clinical Vignette (11 questions)

1. A 58-year-old woman with a large posterior fossa meningioma and mildly elevated intracranial pressure is scheduled for elective suboccipital craniotomy. The attending neuroanesthesiologist selects isoflurane rather than halothane for maintenance. Which of the following best explains the pharmacological basis for this choice?

A) Isoflurane is preferred because it produces greater peripheral vasodilation than halothane, maintaining cardiac output and systemic blood pressure more reliably in elderly patients undergoing prolonged posterior fossa surgery in the sitting position
B) Isoflurane is preferred because it produces substantially less cerebral blood flow increase than halothane at equivalent MAC fractions — typically 20 to 40% above baseline versus halothane's 200% or more at 2 MAC — and provides greater CMRO2 suppression per MAC including the capacity to produce isoelectric EEG; both properties reduce the burden on intracranial compliance in a patient with already elevated intracranial pressure
C) Isoflurane is preferred because it has a lower blood-gas solubility coefficient than halothane, allowing faster induction and emergence and more precise titration of anesthetic depth in a patient where rapid neurological assessment at the end of surgery is essential
D) Isoflurane is preferred because it does not sensitize the myocardium to catecholamine-induced arrhythmias, unlike halothane; posterior fossa surgery in the sitting position frequently requires epinephrine infiltration of the scalp, and the catecholamine sensitization threshold under halothane is unacceptably low for this use
E) Isoflurane is preferred because it provides superior postoperative analgesia through opioid receptor sensitization, reducing the postoperative narcotic requirement in a patient where respiratory depression is particularly hazardous after posterior fossa surgery

ANSWER: B

Rationale:

Option B is correct. The neuroanesthesia selection of isoflurane over halothane in a patient with elevated ICP rests on two converging cerebrovascular pharmacological advantages. First, isoflurane produces a substantially smaller increase in cerebral blood flow at equivalent MAC fractions: approximately 20 to 40% above baseline at 1 MAC, compared to halothane's 200% or more at 2 MAC. In a patient with reduced intracranial compliance from a large meningioma, minimizing the anesthetic-induced increment in intracranial blood volume is a direct clinical priority. Second, isoflurane provides greater CMRO2 suppression per MAC and is the only volatile agent capable of producing isoelectric EEG at clinically achievable concentrations — a property exploited for deliberate hypotension or temporary vessel occlusion during vascular neurosurgical procedures. Together these properties make isoflurane the preferred volatile agent when a volatile technique is used in neurosurgical patients.

Option A: Option A is incorrect because while isoflurane does produce greater peripheral vasodilation than halothane, this hemodynamic property — though relevant to general cardiovascular management — is not the primary pharmacological rationale for choosing isoflurane over halothane in the neuroanesthesia context; the CBF and CMRO2 profile is the governing consideration.
Option C: Option C is incorrect because isoflurane does not have lower blood-gas solubility than halothane; in fact desflurane and sevoflurane have lower solubility than isoflurane, and blood-gas solubility is not the basis for the neuroanesthetic preference for isoflurane over halothane.
Option D: Option D is incorrect because while halothane's catecholamine sensitization is a real pharmacological concern, scalp infiltration with epinephrine during craniotomy is not the primary reason for the agent selection; the cerebrovascular profile drives the choice, and other measures (dose limitation) manage the epinephrine concern.
Option E: Option E is incorrect because isoflurane does not provide postoperative analgesia through opioid receptor sensitization; inhalational agents do not have clinically meaningful analgesic properties through opioid pathways in the postoperative period.

2. A 71-year-old man with three-vessel coronary artery disease and preserved ejection fraction (EF 58%) undergoes elective coronary artery bypass grafting. The cardiac anesthesiologist is choosing between sevoflurane-based maintenance and propofol TIVA. The patient has no neurological comorbidities. Which of the following provides the strongest pharmacological rationale for selecting sevoflurane over propofol for this patient?

A) Sevoflurane should be selected because it produces greater peripheral vasodilation than propofol, maintaining coronary perfusion pressure more reliably during the periods of hemodynamic instability that accompany cardiopulmonary bypass
B) Sevoflurane should be selected because it does not inhibit hypoxic pulmonary vasoconstriction, preserving ventilation-perfusion matching during the single-lung ventilation periods that are required for internal mammary artery harvest in most CABG procedures
C) Propofol should be selected over sevoflurane because its antioxidant properties reduce free radical generation during reperfusion, providing superior myocardial protection compared to any volatile agent; sevoflurane has no demonstrated cardioprotective properties in human cardiac surgery
D) Sevoflurane should be selected because clinical trials in cardiac surgical patients have demonstrated that volatile anesthetic-based maintenance reduces postoperative cardiac troponin release compared to propofol TIVA, consistent with anesthetic-induced myocardial preconditioning through mitochondrial KATP channel activation via adenosine receptor signaling; this cardioprotective property is not replicated by propofol
E) The choice between sevoflurane and propofol is pharmacologically equivalent for this patient because both agents reduce myocardial oxygen demand by lowering heart rate and blood pressure through equivalent mechanisms; the selection should be based entirely on the anesthesiologist's familiarity with each technique

ANSWER: D

Rationale:

Option D is correct. In a patient with significant coronary artery disease undergoing CABG with preserved ejection fraction and no neurological contraindications to volatile agents, the strongest pharmacological rationale for selecting sevoflurane is anesthetic-induced myocardial preconditioning. Clinical trials in cardiac surgical patients have demonstrated that volatile anesthetic-based maintenance — particularly with isoflurane and sevoflurane — reduces postoperative cardiac troponin release compared to propofol TIVA. The proposed mechanism parallels ischemic preconditioning: activation of mitochondrial ATP-sensitive potassium (KATP) channels through adenosine receptor signaling helps preserve mitochondrial membrane potential during the ischemic period of cardioplegia, reducing ischemia-reperfusion injury upon reperfusion. Propofol does not activate this pathway and does not replicate this cardioprotective effect, despite its antioxidant properties. For a patient undergoing CABG where myocardial protection during ischemia-reperfusion is a primary concern, this pharmacological distinction favors the volatile agent.

Option A: Option A is incorrect because peripheral vasodilation and coronary perfusion pressure maintenance are general hemodynamic properties of volatile agents, not the specific pharmacological rationale that distinguishes volatile from TIVA maintenance in this cardiac context; propofol also reduces afterload.
Option B: Option B is incorrect because CABG does not require single-lung ventilation; internal mammary artery harvest is performed under conventional two-lung ventilation; HPV preservation is irrelevant to this case.
Option C: Option C is incorrect because the claim that sevoflurane has no demonstrated cardioprotective properties in human cardiac surgery is factually wrong; multiple trials have demonstrated reduced troponin release with volatile maintenance; and while propofol's antioxidant properties are real, they do not equal or exceed volatile-agent preconditioning in the clinical evidence base.
Option E: Option E is incorrect because sevoflurane and propofol are not pharmacologically equivalent for cardiac protection in CABG; the KATP-channel-mediated preconditioning of volatile agents is a specific pharmacological property not shared by propofol, making the choice pharmacologically meaningful, not merely a matter of technique familiarity.

3. A 45-year-old man with a right temporal glioblastoma and 2 cm of surrounding vasogenic edema on MRI presents for elective craniotomy. He was started on dexamethasone 4 mg IV every 6 hours three days before surgery. On the morning of surgery, the neurosurgeon notes that his preoperative neurological examination has improved and his papilledema has partially resolved. The anesthesiologist attributes the improvement to the dexamethasone. Which of the following correctly explains the pharmacological mechanism responsible?

A) Dexamethasone reduced the vasogenic edema surrounding the tumor by decreasing blood-brain barrier permeability and suppressing inflammatory mediator production by the tumor; vasogenic edema results from protein-rich fluid leaking through a disrupted blood-brain barrier into the extracellular space, and dexamethasone's anti-inflammatory action on the barrier directly reduces this leakage over hours to days
B) Dexamethasone reduced ICP by stimulating the reabsorption of cerebrospinal fluid through the arachnoid granulations, lowering the CSF component of intracranial volume; this mechanism acts within 30 minutes of administration, explaining the rapid clinical improvement seen over three days
C) Dexamethasone reduced the cytotoxic component of the edema by restoring the activity of the Na/K-ATPase ion pump in ischemic neurons adjacent to the tumor, correcting the intracellular sodium and water accumulation that was contributing to brain swelling
D) Dexamethasone reduced ICP by causing cerebral vasoconstriction through glucocorticoid receptor activation on cerebrovascular smooth muscle, reducing intracranial blood volume; this mechanism is equivalent in speed and magnitude to controlled hyperventilation and acts independently of any effect on blood-brain barrier permeability
E) Dexamethasone reduced the edema by acting as an osmotic agent, drawing water from the edematous brain parenchyma into the systemic circulation along the osmotic gradient established by the elevated serum cortisol levels produced by the exogenous glucocorticoid

ANSWER: A

Rationale:

Option A is correct. The clinical improvement in this patient reflects dexamethasone's well-established mechanism of action on vasogenic cerebral edema. Glioblastoma disrupts the blood-brain barrier through secretion of vascular endothelial growth factor (VEGF) and other mediators that increase barrier permeability, allowing protein-rich plasma fluid to leak into the extracellular space of the surrounding brain — vasogenic edema. Dexamethasone reduces this leakage by decreasing blood-brain barrier permeability and suppressing the tumor-associated inflammatory mediator production that drives the barrier disruption. The clinical effect develops over hours to days — explaining why three days of preoperative treatment produces meaningful improvement by the morning of surgery. This slow onset distinguishes dexamethasone from osmotic agents (mannitol, which acts within 15 to 30 minutes) and makes it unsuitable for acute ICP rescue but ideal for preoperative optimization. Standard dosing is 4 mg IV every 6 hours for perioperative brain tumor edema.

Option B: Option B is incorrect because dexamethasone does not act by stimulating CSF reabsorption through arachnoid granulations; that is not an established mechanism of its ICP-lowering effect; and the onset is not 30 minutes — dexamethasone requires hours to days to produce its clinical effect.
Option C: Option C is incorrect because dexamethasone is not effective for cytotoxic edema, which involves intracellular swelling from ion pump failure in ischemic cells; dexamethasone specifically reduces vasogenic edema and is not recommended for cytotoxic edema as in ischemic stroke or traumatic brain injury.
Option D: Option D is incorrect because dexamethasone does not reduce ICP through direct cerebrovascular smooth muscle constriction via glucocorticoid receptors; its mechanism is anti-inflammatory action on the blood-brain barrier, not vasoconstriction; and the characterization of its speed as equivalent to hyperventilation is incorrect.
Option E: Option E is incorrect because dexamethasone is not an osmotic agent and does not work through an osmotic gradient; its mechanism is receptor-mediated anti-inflammatory action, not a physicochemical osmotic effect on tissue water.

4. A 62-year-old woman is undergoing right lower lobectomy for non-small cell lung cancer under one-lung ventilation. She is being maintained on isoflurane at 1.0 MAC. Forty minutes into one-lung ventilation her SpO2 has fallen from 98% to 88% despite optimizing the FiO2 to 1.0 and confirming correct double-lumen tube position. The anesthesiologist considers switching anesthetic maintenance technique. Which of the following is the most pharmacologically appropriate intervention to improve oxygenation in this setting?

A) Increase the isoflurane concentration to 1.5 MAC to deepen anesthesia; deeper volatile anesthesia produces greater bronchodilation in the ventilated lung, improving its compliance and reducing the work of breathing against the collapsed right lung
B) Add nitrous oxide 50% to the inspired gas mixture; nitrous oxide does not inhibit hypoxic pulmonary vasoconstriction and its MAC-sparing effect will allow a reduction in isoflurane concentration that will secondarily improve oxygenation
C) Switch maintenance to propofol TIVA; isoflurane inhibits hypoxic pulmonary vasoconstriction in a dose-dependent fashion, increasing blood flow through the collapsed non-ventilated lung and worsening the intrapulmonary shunt; propofol does not inhibit HPV, allowing restoration of the physiological diversion of blood flow away from the non-ventilated lung
D) Administer intravenous ketamine 0.5 mg/kg; ketamine's sympathomimetic properties cause selective pulmonary vasoconstriction in the non-ventilated lung that mimics and amplifies the hypoxic pulmonary vasoconstriction response, improving ventilation-perfusion matching
E) Switch from isoflurane to desflurane at an equivalent MAC; desflurane uniquely preserves hypoxic pulmonary vasoconstriction among the volatile agents because its sympathomimetic surge property increases pulmonary vascular tone in poorly ventilated lung regions

ANSWER: C

Rationale:

Option C is correct. The pharmacological explanation for the hypoxemia is isoflurane-mediated inhibition of hypoxic pulmonary vasoconstriction (HPV). HPV is the critical physiological mechanism that diverts pulmonary blood flow away from poorly ventilated or atelectatic lung regions — in this case the collapsed right lung during one-lung ventilation — toward better-ventilated regions, thereby limiting the intrapulmonary shunt fraction. Isoflurane, like all currently used volatile anesthetic agents, inhibits HPV in a dose-dependent fashion at clinically used concentrations. At 1.0 MAC, this inhibition is clinically significant: blood continues to flow through the collapsed right lung, contributing to an increasing shunt fraction and progressive hypoxemia. Propofol does not inhibit HPV, allowing the physiological vasoconstriction to continue operating in the non-ventilated lung. Switching to propofol-remifentanil TIVA is the pharmacologically targeted intervention that addresses the root cause of the hypoxemia.

Option A: Option A is incorrect because increasing isoflurane to 1.5 MAC would worsen HPV inhibition, increasing shunt and worsening hypoxemia; bronchodilation of the ventilated lung is not the relevant mechanism for improving oxygenation in this scenario.
Option B: Option B is incorrect because nitrous oxide does inhibit HPV to some degree; additionally, adding 50% nitrous oxide would reduce the FiO2 from 1.0 to 0.5, which directly worsens oxygenation in a patient with critical hypoxemia — this intervention would be dangerous, not beneficial.
Option D: Option D is incorrect because ketamine does not selectively cause pulmonary vasoconstriction in the non-ventilated lung that amplifies HPV; this is not an established pharmacological property of ketamine, and subanaesthetic doses of ketamine would not produce the claimed selective effect.
Option E: Option E is incorrect because desflurane does not preserve HPV; all volatile agents — isoflurane, sevoflurane, and desflurane — inhibit HPV to similar degrees at equivalent MAC fractions; desflurane's sympathomimetic surge property is specific to rapid concentration increases and does not selectively augment pulmonary vascular tone in hypoxic lung regions.

5. A 38-year-old man is undergoing awake craniotomy for resection of a left frontal glioma abutting the primary motor cortex. He is maintained on propofol and remifentanil infusions using the asleep-awake-asleep technique. During the cortical stimulation mapping phase, the patient suddenly develops rhythmic clonic movements of the right hand that spread to the right arm, consistent with a focal motor seizure triggered by cortical stimulation. The neurosurgeon irrigates the cortex with cold saline without termination of the seizure. Which of the following is the most pharmacologically appropriate next intervention?

A) Immediately restart the propofol infusion at the full induction dose (200 mg/kg/min) and administer succinylcholine to facilitate emergency intubation, converting to general anesthesia as the seizure represents a life-threatening emergency requiring airway protection
B) Administer intravenous phenytoin 15 to 20 mg/kg at the maximum infusion rate; phenytoin is the first-line agent for intraoperative seizure termination because of its sodium channel mechanism and lack of sedation, which preserves the ability to continue cortical mapping immediately after the seizure terminates
C) Administer intravenous adenosine 6 mg to produce transient cardiac standstill; the resulting brief cerebral hypoperfusion will terminate the seizure by reducing neuronal excitability below the threshold for sustained firing
D) Administer intravenous thiopental 250 mg; thiopental's potent GABA-A agonist properties provide the most rapid seizure termination of any available agent, and its short redistribution half-life allows resumption of the awake phase within 5 minutes
E) Administer a small intravenous bolus of propofol (20 to 40 mg) or midazolam (1 to 2 mg); propofol provides rapid seizure termination through GABA-A potentiation with minimal residual sedation at small doses, allowing potential return to cooperation for continued mapping after the seizure resolves; this is the pharmacological approach specifically suited to awake craniotomy, where maintaining the possibility of awakening for mapping is the design constraint

ANSWER: E

Rationale:

Option E is correct. Intraoperative seizure during awake craniotomy is a recognized complication managed with a stepwise approach specifically designed around the pharmacological constraints of the technique. The first maneuver is irrigation of the seizure focus with iced saline, which can terminate focal cortical stimulation-induced seizures through local cooling. When this fails, the pharmacological intervention must balance rapid seizure termination against preservation of the patient's ability to cooperate for mapping. A small bolus of propofol (20 to 40 mg) or midazolam (1 to 2 mg) achieves this balance: propofol provides rapid seizure termination through potentiation of GABA-A receptors with brief duration at small bolus doses due to its rapid redistribution; midazolam provides reliable seizure termination through the same mechanism with somewhat longer sedation. Both allow potential return to an awake and cooperative state for continued mapping — the defining pharmacological requirement of the awake craniotomy technique. If the seizure cannot be controlled with these measures, conversion to general anesthesia becomes necessary.

Option A: Option A is incorrect because immediate conversion to general anesthesia with full induction doses and succinylcholine is not the first pharmacological response to an intraoperative focal seizure during awake craniotomy; small-dose propofol or midazolam are tried first; and succinylcholine's ICP-raising fasciculation effect is an unnecessary risk when propofol induction alone suffices if conversion becomes necessary.
Option B: Option B is incorrect because intravenous phenytoin is not the first-line agent for acute intraoperative seizure termination in awake craniotomy; its slow infusion rate (maximum 50 mg/min to avoid cardiac toxicity) means therapeutic levels are not achieved rapidly enough for acute control, and its lack of sedation is irrelevant if it does not terminate the seizure promptly.
Option C: Option C is incorrect because adenosine-induced cardiac standstill to cause cerebral hypoperfusion is not an established or acceptable treatment for intraoperative seizure; this would cause dangerous global cerebral ischemia and is not pharmacologically justified.
Option D: Option D is incorrect because thiopental at 250 mg would produce deep general anesthesia incompatible with awakening for cortical mapping within 5 minutes; thiopental's redistribution half-life does not support rapid return to a cooperative awake state at this dose, making it unsuitable for the awake craniotomy context.

6. A 55-year-old man with ischemic cardiomyopathy (ejection fraction 20%) and a right parietal meningioma causing elevated intracranial pressure (ICP 24 mmHg) requires urgent craniotomy. His blood pressure is 88/60 mmHg on a low-dose norepinephrine infusion. The anesthesiologist must select an induction agent. Which of the following best identifies the agent of choice and the pharmacological rationale integrating both the cardiac and neurological constraints?

A) Propofol 2 mg/kg is the agent of choice because it reduces CMRO2 and CBF more reliably than any other induction agent, and its vasodilatory mechanism of MAP reduction is better tolerated by the compromised ventricle than agents that cause direct myocardial depression
B) Ketamine 1.5 mg/kg is the agent of choice because its sympathomimetic properties maintain or increase cardiac output and blood pressure, directly counteracting the hemodynamic fragility from the low ejection fraction; its effects on ICP are a manageable concern given the urgent nature of the case
C) Thiopental 3 to 5 mg/kg is the agent of choice because it produces the most profound and reliable reduction in CMRO2 and ICP of any induction agent; in a patient with elevated ICP, the neurological protection it provides outweighs its myocardial depressant properties
D) Etomidate 0.3 mg/kg is the agent of choice; it reduces CMRO2 and CBF — directly addressing the elevated ICP — while being the most hemodynamically neutral induction agent available, with minimal effects on cardiac contractility, heart rate, or systemic vascular resistance; this combination of cerebrovascular benefit and cardiovascular safety is uniquely suited to a patient with both severe ventricular dysfunction and elevated ICP
E) Midazolam 0.1 mg/kg is the agent of choice because its benzodiazepine-mediated GABA-A potentiation reliably reduces ICP without any negative inotropic effect; it is the only induction agent with a pharmacological reversal agent (flumazenil), providing an additional safety margin in a hemodynamically fragile patient

ANSWER: D

Rationale:

Option D is correct. This patient presents a dual pharmacological constraint: severely compromised cardiac function (EF 20%, already on vasopressor support) makes hemodynamic stability during induction critical, while elevated ICP demands an induction agent that reduces rather than increases cerebral blood flow and metabolic rate. Etomidate uniquely satisfies both requirements simultaneously. Its cardiovascular profile is the most neutral of any available induction agent — it produces minimal changes in heart rate, contractility, and systemic vascular resistance, making it the preferred agent for cardiovascular compromise. Simultaneously, etomidate reduces CMRO2 and CBF, directly addressing the elevated ICP. The GA-03 module explicitly identifies etomidate as the preferred induction agent when cardiovascular compromise limits propofol use in patients with elevated ICP. Propofol, while pharmacologically preferred for ICP management in patients with adequate cardiovascular reserve, would be expected to produce dangerous hypotension in a patient already vasopressor-dependent with an EF of 20%.

Option A: Option A is incorrect because propofol at the stated dose would produce profound hypotension in this hemodynamically fragile patient; while its vasodilatory mechanism of MAP reduction is preferable to myocardial depression in patients with mild-moderate LV dysfunction, a patient with EF 20% on vasopressor support has no tolerance for the degree of afterload reduction and myocardial depression propofol produces at induction doses.
Option B: Option B is incorrect because ketamine's sympathomimetic properties increase CBF and may increase ICP through sympathomimetic-mediated CBF elevation; this property is a direct contraindication in a patient with already-elevated ICP and reduced intracranial compliance, making ketamine's cardiac benefit insufficient to justify its neurological risk in this context.
Option C: Option C is incorrect because thiopental at standard induction doses produces significant myocardial depression and vasodilation that would be poorly tolerated in a patient with EF 20% on vasopressor support; the neurological benefit does not outweigh this cardiovascular liability when etomidate provides equivalent neurological benefit without cardiovascular compromise.
Option E: Option E is incorrect because midazolam at 0.1 mg/kg (a sedative, not an induction dose) does not reliably produce unconsciousness or the degree of CMRO2/CBF reduction needed for induction in a patient with elevated ICP; flumazenil reversibility is not a standard pharmacological selection criterion for induction agents in this context.

7. A 76-year-old woman with longstanding poorly controlled hypertension (baseline MAP 115 mmHg) is undergoing cervical spine fusion under isoflurane at 1.2 MAC with intraoperative somatosensory evoked potential (SSEP) monitoring. During a period of surgical bleeding, her MAP falls to 60 mmHg. The neurophysiology team reports a 40% decline in SSEP amplitude. The surgeon asks the anesthesiologist to explain the cause. Which of the following is the most accurate pharmacological explanation?

A) Two compounding mechanisms explain the SSEP decline: chronic hypertension has shifted the cerebral autoregulatory curve rightward, raising her effective lower autoregulatory limit to approximately 70 to 80 mmHg rather than the textbook 50 mmHg; simultaneously isoflurane at 1.2 MAC has substantially impaired whatever autoregulatory capacity remained, rendering her cerebrovascular bed largely pressure-passive; at a MAP of 60 mmHg she is therefore below both her shifted autoregulatory lower limit and operating in a pressure-passive state, so CBF has fallen proportionally with MAP, reducing spinal cord and cerebral perfusion sufficient to impair SSEP generation
B) The SSEP decline is caused solely by isoflurane's direct dose-dependent suppression of somatosensory cortical processing; at 1.2 MAC, isoflurane has exceeded the threshold above which SSEPs become unreliable regardless of blood pressure, and the MAP of 60 mmHg is within safe autoregulatory range for any adult patient
C) The SSEP decline reflects spinal cord ischemia caused by hypotension in a patient with likely vertebral artery atherosclerosis from chronic hypertension; the volatile anesthetic concentration is not a contributing factor because isoflurane at 1.2 MAC preserves autoregulation in all adult patients
D) The SSEP decline is a normal physiological response to surgical manipulation of the cervical spine; changes in SSEP amplitude of up to 50% during positioning and retraction are expected and do not require pharmacological intervention
E) The SSEP decline is caused by isoflurane-induced inhibition of the Na/K-ATPase pump in spinal cord neurons, reducing the electrochemical gradient needed to generate action potentials; this effect is independent of blood pressure and would occur at any MAP once isoflurane concentration exceeds 1.0 MAC

ANSWER: A

Rationale:

Option A is correct. This scenario requires integrating two GA-03 concepts with clinical physiology about chronic hypertension. The first principle: chronic hypertension remodels the cerebrovascular bed and shifts the entire autoregulatory curve rightward. In a patient with a baseline MAP of 115 mmHg, the lower limit of effective autoregulation is likely 70 to 80 mmHg rather than the textbook 50 mmHg established in normotensive subjects. A MAP of 60 mmHg is therefore already below this patient's shifted autoregulatory threshold. The second principle: isoflurane at 1.2 MAC substantially impairs cerebral autoregulation, converting the cerebrovascular response toward a pressure-passive state. The combination is compounding — the rightward shift from hypertension narrows the safe autoregulatory window, and the volatile-agent-induced impairment eliminates residual compensatory vasodilation. At 60 mmHg MAP in this pressure-passive, right-shifted cerebrovascular system, CBF falls in direct proportion to MAP, reducing perfusion of the spinal cord and somatosensory pathways sufficiently to impair SSEP amplitude. The correct intervention is to raise MAP promptly with a vasopressor.

Option B: Option B is incorrect because SSEP suppression by isoflurane is dose-dependent but SSEPs — unlike MEPs — can generally be monitored at volatile concentrations up to approximately 0.5 to 1.0 MAC; and 60 mmHg MAP is not within safe autoregulatory range for this patient given her chronic hypertension and rightward-shifted autoregulatory curve.
Option C: Option C is incorrect because isoflurane at 1.2 MAC does not preserve autoregulation in all adult patients — it substantially impairs it, which is the central pharmacological principle of this scenario; and attributing the SSEP change solely to vertebral artery disease ignores the anesthetic contribution.
Option D: Option D is incorrect because a 40% amplitude decline is not an expected normal response to surgical manipulation; the threshold for concern in most neurophysiology monitoring protocols is a greater than 50% amplitude decline or 10% latency increase, and a 40% decline warrants prompt investigation, not dismissal.
Option E: Option E is incorrect because isoflurane does not inhibit the Na/K-ATPase pump; volatile agents produce CNS depression through GABA-A potentiation and NMDA inhibition, not through direct pump blockade, and the SSEP changes in this scenario are hemodynamically mediated, not pharmacologically mediated through pump inhibition.

8. A 49-year-old man weighing 80 kg is undergoing resection of a scalp lesion under halothane anesthesia. The surgeon requests infiltration of 20 mL of lidocaine 1% with epinephrine 1:100,000 for local hemostasis. The anesthesiologist pauses before allowing the infiltration to proceed. Which of the following correctly calculates the epinephrine dose and identifies the appropriate clinical response?

A) The planned infiltration delivers 20 mcg of epinephrine (20 mL x 1 mcg/mL), which equals 0.25 mcg/kg in an 80 kg patient — well below the halothane arrhythmia threshold of 1.5 to 2 mcg/kg; the infiltration can proceed without modification
B) The planned infiltration delivers 2000 mcg of epinephrine (20 mL x 100 mcg/mL), which equals 25 mcg/kg — far above any safe threshold; the surgeon must use plain lidocaine without any epinephrine under halothane anesthesia, as no safe epinephrine dose exists with this agent
C) The planned infiltration delivers 200 mcg of epinephrine (20 mL x 10 mcg/mL from a 1:100,000 solution), which equals 2.5 mcg/kg in an 80 kg patient — exceeding the halothane arrhythmia threshold of approximately 1.5 to 2 mcg/kg; the anesthesiologist should require either a reduction in the total epinephrine dose to below the arrhythmia threshold or a switch to a volatile agent with a higher threshold such as isoflurane or sevoflurane before infiltration
D) The planned infiltration delivers 200 mcg of epinephrine (2.5 mcg/kg), which is below the halothane arrhythmia threshold of 5 to 7 mcg/kg; the infiltration can proceed, but the anesthesiologist should monitor for junctional rhythm as a sign of early catecholamine sensitization and reduce the inspired halothane concentration by 0.2 MAC as a precaution
E) The epinephrine dose in a 1:100,000 solution is 0.1 mcg/mL; the 20 mL volume delivers 2 mcg total (0.025 mcg/kg), which is inconsequential at any volatile anesthetic concentration and requires no dose modification

ANSWER: C

Rationale:

Option C is correct. The pharmacological calculation requires two steps. First, the epinephrine concentration: a 1:100,000 solution contains 1 mg (1000 mcg) per 100 mL, which equals 10 mcg/mL. Second, the total dose: 20 mL x 10 mcg/mL = 200 mcg. In an 80 kg patient, this is 200 ÷ 80 = 2.5 mcg/kg. The GA-03 module establishes that the threshold for epinephrine-induced ventricular arrhythmias under halothane is approximately 1.5 to 2 mcg/kg. The planned dose of 2.5 mcg/kg exceeds this threshold, placing the patient at risk for ventricular ectopy, bigeminy, or ventricular fibrillation. The appropriate clinical response is to require dose reduction — either by using a more dilute epinephrine solution, infiltrating a smaller volume, or both — to bring the total epinephrine dose below approximately 1.5 mcg/kg (120 mcg maximum in this patient). Alternatively, switching to isoflurane or sevoflurane before infiltration would raise the threshold to 7 to 10 mcg/kg, providing a safe margin for the planned dose.

Option A: Option A is incorrect because 1:100,000 is 10 mcg/mL, not 1 mcg/mL; a 1:1,000,000 solution would be 1 mcg/mL; the dose calculation in Option A reflects a 100-fold concentration error.
Option B: Option B is incorrect because 1:100,000 is 10 mcg/mL, not 100 mcg/mL; the total dose is 200 mcg, not 2000 mcg; and while the dose does exceed the halothane threshold, the claim that no safe epinephrine dose exists under halothane is an overcorrection — the threshold is approximately 1.5 to 2 mcg/kg, and smaller doses are acceptable.
Option D: Option D is incorrect because the halothane arrhythmia threshold is 1.5 to 2 mcg/kg, not 5 to 7 mcg/kg; those higher values describe the threshold under isoflurane; accepting 2.5 mcg/kg under halothane as safe based on an incorrect threshold would expose the patient to real arrhythmia risk.
Option E: Option E is incorrect because a 1:100,000 solution contains 10 mcg/mL, not 0.1 mcg/mL; this represents a 100-fold concentration underestimate.

9. A 33-year-old woman with well-controlled juvenile myoclonic epilepsy on levetiracetam presents for elective lumbar disc surgery. The anesthesiologist plans sevoflurane maintenance at 1.0 to 1.2 MAC with moderate controlled hyperventilation to a PaCO2 of 32 to 35 mmHg for surgical positioning purposes. A medical student asks whether sevoflurane is safe in a patient with a seizure disorder and whether the hyperventilation will increase seizure risk. Which of the following is the most accurate response?

A) The plan is unsafe because sevoflurane shares enflurane's epileptogenic properties at concentrations above 1.0 MAC; all halogenated volatile agents carry equivalent seizure risk in patients with epilepsy, and any volatile agent combined with hyperventilation is contraindicated in this population
B) The plan is safe on both counts: sevoflurane does not have clinically meaningful epileptogenic potential and is not contraindicated in patients with epilepsy — isolated reports of EEG spike activity during sevoflurane induction at high concentrations in some pediatric patients are not classified as clinically significant epileptogenicity; and moderate hyperventilation to PaCO2 32 to 35 mmHg does not reach the hypocapnic threshold that markedly potentiates seizure risk, which is specifically a concern with enflurane at PaCO2 values below 30 mmHg in combination with concentrations above 2 MAC
C) The plan requires modification: sevoflurane is acceptable in epileptic patients but hyperventilation to any degree is absolutely contraindicated because any reduction in PaCO2 below 40 mmHg lowers the seizure threshold in patients with a seizure disorder, regardless of which volatile agent is used
D) The plan is unsafe because sevoflurane at 1.0 MAC produces burst suppression in patients with epilepsy, and the transition from burst suppression back to normal EEG activity during emergence can trigger refractory status epilepticus in susceptible patients
E) The plan requires substitution of isoflurane for sevoflurane; isoflurane is the only volatile agent with a documented antiepileptiform EEG profile (burst suppression) that provides active seizure protection in patients with epilepsy; sevoflurane lacks this property and is not recommended in patients with known seizure disorders

ANSWER: B

Rationale:

Option B is correct. This question requires precise discrimination between enflurane's unique epileptogenic profile and the safety of the other modern volatile agents in epileptic patients. Sevoflurane does not have clinically meaningful epileptogenic potential. While there are isolated reports of EEG spike activity during high-concentration sevoflurane induction in some pediatric patients, clinically overt seizures attributable to sevoflurane in adults are exceedingly rare, and sevoflurane is not classified as an epileptogenic agent for clinical purposes. It is not contraindicated in patients with epilepsy and is routinely used for neurosurgical procedures in this population. Regarding the hyperventilation component: the specific danger of hypocapnia potentiating seizure risk applies to enflurane — the combination of enflurane above approximately 2 MAC with hypocapnia (particularly PaCO2 below 30 mmHg) synergistically lowers the seizure threshold. This interaction is not a property of sevoflurane; moderate hyperventilation to PaCO2 32 to 35 mmHg during sevoflurane anesthesia does not confer meaningful additional seizure risk.

Option A: Option A is incorrect because sevoflurane does not share enflurane's epileptogenic properties; enflurane is the single volatile agent with documented clinically significant epileptogenic potential, and this is a unique property, not a class effect.
Option C: Option C is incorrect because the absolute prohibition on any hyperventilation in epileptic patients under any volatile agent is not supported pharmacologically; the hyperventilation concern is specifically linked to the enflurane-hypocapnia interaction, not to all volatile agents at any degree of hypocapnia.
Option D: Option D is incorrect because sevoflurane at 1.0 MAC does not produce burst suppression — that level of EEG suppression requires higher concentrations and is more reliably achieved with isoflurane; and emergence-triggered refractory status epilepticus from burst suppression recovery is not an established pharmacological risk profile of sevoflurane.
Option E: Option E is incorrect because isoflurane's burst suppression property at high doses is an antiepileptiform pattern useful in specific settings, but it is not the basis for recommending isoflurane over sevoflurane in routine epileptic patients; both agents are acceptable, and sevoflurane is not contraindicated in this population.

10. A 67-year-old man is in the neurosurgical ICU on postoperative day 1 following resection of a left temporal glioblastoma. His ICP monitor reads 32 mmHg (normal below 20 mmHg) and is rising. He is already receiving dexamethasone 4 mg IV every 6 hours started preoperatively. The intensivist has three additional pharmacological options available: a mannitol infusion, a furosemide bolus, and an additional dose of dexamethasone. Rank these three agents from fastest to slowest expected onset of ICP reduction in this acute setting, and identify which is most appropriate for immediate rescue.

A) Dexamethasone is fastest because the patient already has therapeutic glucocorticoid levels from preoperative dosing — an additional bolus dose can reduce ICP within 15 to 30 minutes by rapidly stabilizing blood-brain barrier permeability; mannitol is intermediate; furosemide is slowest
B) Furosemide is fastest because its inhibition of the Na-K-2Cl cotransporter in the kidney produces immediate diuresis within 5 minutes of IV administration, rapidly reducing total body water and intracranial volume; mannitol is intermediate; dexamethasone is slowest
C) All three agents reduce ICP through equivalent mechanisms and at equivalent speeds when given intravenously; the choice among them is determined by renal function and electrolyte status, not by onset time; any of the three would be equally appropriate for immediate ICP rescue
D) Mannitol is fastest for initial ICP reduction; dexamethasone is intermediate (effective within 1 to 2 hours when additional doses are given on top of an existing regimen); furosemide is slowest because its ICP-lowering effect requires 24 to 48 hours of continuous diuresis to meaningfully reduce brain water content
E) Mannitol is the correct agent for immediate acute ICP rescue: its osmotic mechanism produces maximal effect within 15 to 30 minutes of IV administration, making it the fastest available pharmacological ICP-lowering intervention; furosemide may be added as a synergistic adjunct with a somewhat slower and more sustained effect; dexamethasone operates over hours to days and has already been administered — an additional dose will not rescue an acutely rising ICP on a clinically meaningful timescale

ANSWER: E

Rationale:

Option E is correct. This question requires applying the distinct pharmacokinetic profiles of three ICP-lowering agents to an acute clinical decision. Mannitol's osmotic mechanism — drawing free water from brain parenchyma into the intravascular compartment along the osmotic gradient — produces its maximal effect within 15 to 30 minutes of IV administration and is sustained for 90 to 120 minutes. This rapid onset makes mannitol the correct pharmacological choice for acute ICP rescue in a patient with rising ICP and an ICP reading of 32 mmHg. Furosemide can be combined with mannitol in acute ICP management — the combination produces synergistic diuresis and more sustained ICP reduction than either agent alone — but its onset is slower than mannitol's osmotic effect and it functions best as a complementary adjunct. Dexamethasone acts over hours to days by reducing blood-brain barrier permeability and inflammatory mediator production; it is already being administered at its standard perioperative dose; an additional bolus dose will not produce meaningful acute ICP reduction on the timescale of a rising ICP emergency. For vasogenic edema from a glioblastoma, the dexamethasone is appropriately continued for its sustained effect, but it cannot serve as the acute rescue agent.

Option A: Option A is incorrect because dexamethasone's onset is hours to days regardless of pre-existing levels — therapeutic glucocorticoid concentrations do not enable a 15 to 30 minute acute ICP response from an additional dose; the mechanism is too slow for acute rescue.
Option B: Option B is incorrect because furosemide, while it does produce rapid renal diuresis, its ICP-lowering effect through total body water reduction and CSF production inhibition operates more slowly than mannitol's direct osmotic effect on brain water; furosemide alone is not the first-line agent for acute ICP rescue.
Option C: Option C is incorrect because the three agents have substantially different mechanisms and onset times — they are not pharmacologically equivalent for acute ICP management; onset time is the critical pharmacological variable in this setting.
Option D: Option D is incorrect because dexamethasone does not become fast-acting when added to an existing regimen; its mechanism is receptor-mediated anti-inflammatory action that requires gene transcription and protein synthesis, which cannot be accelerated by additional dosing on top of a steady-state regimen.

11. A 52-year-old woman is undergoing posterior spinal fusion at T4 to T8 for degenerative kyphosis under sevoflurane at 0.8 MAC with intraoperative MEP (motor evoked potential) monitoring. Thirty minutes into the case the neurophysiology team reports loss of MEP signals bilaterally. The surgeon has not yet begun instrumentation and the surgical field has not changed. Positioning is confirmed correct. Blood pressure is MAP 72 mmHg and the patient is normocapnic. Which of the following is the most pharmacologically appropriate immediate intervention?

A) Increase the sevoflurane concentration to 1.2 MAC to deepen anesthesia; loss of MEP signals during spinal surgery usually reflects insufficient anesthetic depth causing patient movement that interferes with signal recording; deeper anesthesia will stabilize the signals
B) Administer a bolus of intravenous fentanyl 150 mcg; opioid supplementation reduces the required volatile concentration, and the MAC-sparing effect will allow spontaneous recovery of MEP signals within 10 minutes without any change to the volatile anesthetic technique
C) Administer intravenous ketamine 0.5 mg/kg; ketamine's NMDA receptor antagonism reduces central sensitization in somatosensory pathways, enhancing MEP amplitude by increasing cortical excitability; it is the first-line pharmacological adjunct for MEP signal recovery during volatile anesthetic maintenance
D) Reduce or eliminate the sevoflurane and transition to propofol-based TIVA; sevoflurane at 0.8 MAC is already causing dose-dependent MEP suppression — at this concentration MEP amplitude is reduced by 50% or more from baseline; the transition to propofol, which does not suppress MEPs at clinical infusion rates, is the targeted pharmacological intervention to restore interpretable signals
E) Administer neostigmine 2.5 mg with glycopyrrolate to reverse any residual neuromuscular blockade; bilateral MEP loss during spinal surgery most commonly reflects unanticipated accumulation of non-depolarizing neuromuscular blocking agents that abolish the peripheral motor unit responses required for MEP recording

ANSWER: D

Rationale:

Option D is correct. The pharmacological cause of bilateral MEP loss in this scenario — no surgical change, correct positioning, normal hemodynamics — is the volatile anesthetic concentration. At 0.8 MAC sevoflurane, MEP amplitude is reduced by 50% or more from baseline; this dose-dependent suppression of motor cortical and corticospinal excitability makes reliable MEP monitoring unreliable or impossible. The targeted pharmacological intervention is to remove the suppressive agent: reduce or eliminate the sevoflurane and transition to propofol-based TIVA. Propofol does not suppress MEPs at clinical infusion rates and is the standard maintenance technique for cases requiring MEP monitoring. The addition of remifentanil provides analgesia without MEP suppression. Following the transition, MEP signals typically recover as the volatile agent is eliminated from the central nervous system. This is not a new complication — it represents a preventable pharmacological effect of using volatile maintenance in a case that should have been managed with TIVA from the outset.

Option A: Option A is incorrect because increasing the volatile concentration would worsen MEP suppression, not improve it; the relationship between volatile concentration and MEP amplitude is one of increasing suppression with increasing dose — the opposite of what this option proposes.
Option B: Option B is incorrect because fentanyl supplementation may provide modest MAC-sparing effect but does not reliably or rapidly restore MEP signals; opioids do not reverse volatile-agent-mediated MEP suppression, and the pharmacological solution is removal of the volatile agent, not supplementation with opioids.
Option C: Option C is incorrect because ketamine is not the first-line pharmacological agent for MEP signal recovery and does not enhance MEP amplitude by increasing cortical excitability in a manner that reliably overcomes volatile agent suppression at 0.8 MAC; the correct intervention is volatile agent reduction, not ketamine administration.
Option E: Option E is incorrect because while neuromuscular blockade does abolish MEP peripheral recordings and must be assessed (via train-of-four monitoring), the question establishes that this is a case where no neuromuscular blocker was documented as contributing and the MAP and clinical context point to volatile suppression as the cause; neostigmine reversal would be pursued if residual blockade were identified as the cause through train-of-four monitoring.